Form 13-F position report

MEREO BIOPHARMA GROUP PLC ADR

Reported by MORGAN STANLEY

MREO CUSIP 589492107 Manager CIK 0000895421

Reported 785,377 shares, down 1,394,265 (64.0%) from the prior quarter.

Reported value -56.6%; share count -64.0% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 785,377 Quarter-end amount reported
Reported value $2,128,371 Fair value at quarter end
Consecutive quarters held 25 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 51000
2021-12-31 334000
2022-03-31 195000
2022-06-30 118000
2022-09-30 129000
2022-12-31 20587
2023-03-31 6376
2023-06-30 11905
2023-09-30 8634
2023-12-31 175941
2024-03-31 4562874
2024-06-30 747850
2024-09-30 9649561
2024-12-31 12439820
2025-03-31 4904194
2025-06-30 2128371
2025-09-30 6893476
2025-12-31 530787
2026-03-31 5420
2026-06-30 5316

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for MEREO BIOPHARMA GROUP PLC ADR held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Added 16,730 +305 (1.9%) < 0.01% $5,316 2026-08-13
Q1 2026 Reduced 16,425 -1,257,360 (-98.7%) < 0.01% $5,420 2026-05-15
Q4 2025 Reduced 1,273,785 -2,072,562 (-61.9%) < 0.01% $530,787 2026-02-13
Q3 2025 Added 3,346,347 +2,560,970 (326.1%) < 0.01% $6,893,476 2025-11-14
Q2 2025 Reduced 785,377 -1,394,265 (-64.0%) < 0.01% $2,128,371 2025-08-15
Q1 2025 Reduced 2,179,642 -1,374,592 (-38.7%) < 0.01% $4,904,194 2025-05-15
Q4 2024 Added 3,554,234 +1,206,409 (51.4%) < 0.01% $12,439,820 2025-02-14
Q3 2024 Added 2,347,825 +2,140,089 (1030.2%) < 0.01% $9,649,561 2024-11-14
Q2 2024 Reduced 207,736 -1,174,953 (-85.0%) < 0.01% $747,850 2024-08-14
Q1 2024 Added 1,382,689 +1,306,524 (1715.4%) < 0.01% $4,562,874 2024-05-15
Q4 2023 Added 76,165 +69,472 (1038.0%) < 0.01% $175,941 2024-02-13
Q3 2023 Reduced 6,693 -2,326 (-25.8%) < 0.01% $8,634 2023-11-15
Q2 2023 Unchanged 9,019 0 (0.0%) < 0.01% $11,905 2023-08-14
Q1 2023 Reduced 9,019 -18,430 (-67.1%) < 0.01% $6,376 2023-05-15
Q4 2022 Reduced 27,449 -121,642 (-81.6%) < 0.01% $20,587 2023-02-14
Q3 2022 Added 149,091 +43,954 (41.8%) < 0.01% $129,000 2022-11-14
Q2 2022 Reduced 105,137 -68,687 (-39.5%) < 0.01% $118,000 2022-08-15
Q1 2022 Reduced 173,824 -34,844 (-16.7%) < 0.01% $195,000 2022-05-13
Q4 2021 Added 208,668 +187,526 (887.0%) < 0.01% $334,000 2022-02-14
Q3 2021 Reduced 21,142 -34,449 (-62.0%) < 0.01% $51,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

103 managers reported MEREO BIOPHARMA GROUP PLC ADR for Q2 2025.

Managers reporting MEREO BIOPHARMA GROUP PLC ADR in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
JANUS HENDERSON GROUP PLC Reduced 17,688,592 -5,046,529 0.02% $48,112,970 6 qtrs
Rubric Capital Management LP Unchanged 15,307,347 0 0.63% $41,482,910 19 qtrs
Frazier Life Sciences Management L P Added 9,440,112 +1,620,249 1.02% $25,582,704 5 qtrs
MANGROVE PARTNERS Unchanged 8,636,485 0 2.51% $23,404,874 9 qtrs
DEERFIELD MANAGEMENT COMPANY L P SERIES C Unchanged 6,710,429 0 0.33% $18,185,263 5 qtrs
ALKEON CAPITAL MANAGEMENT LLC Unchanged 4,698,100 0 0.02% $12,731,851 19 qtrs
Rock Springs Capital Management LP Reduced 4,465,292 -2,218,955 0.75% $12,100,941 18 qtrs
683 Capital Management LLC Reduced 4,350,000 -285,000 0.77% $11,788,499 11 qtrs
Clearline Capital LP Added 3,618,163 +400,269 0.37% $9,805,222 15 qtrs
The Goldman Sachs Group Inc Added 3,090,068 +964,148 < 0.01% $8,374,084 15 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 15, 2025
Filing type
13F-HR
Position type
SPON ADS

Voting authority reported

Sole
783,358
Shared
0
None
2,019

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.